{"name":"CSPC Ouyi Pharmaceutical Co., Ltd.","slug":"cspc-ouyi-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ABCD","genericName":"ABCD","slug":"abcd","indication":"Other","status":"phase_3"},{"name":"SYHX1901","genericName":"SYHX1901","slug":"syhx1901","indication":"Indication 1","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"SYHX2011","genericName":"SYHX2011","slug":"syhx2011","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"ABCD","genericName":"ABCD","slug":"abcd","phase":"phase_3","mechanism":"ABCD is an investigational drug in phase 3 development by CSPC Ouyi Pharmaceutical Co., Ltd., but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"SYHX1901","genericName":"SYHX1901","slug":"syhx1901","phase":"phase_3","mechanism":"SYHX1901 is a small molecule drug that targets the molecular target.","indications":["Indication 1"],"catalyst":""},{"name":"SYHX2011","genericName":"SYHX2011","slug":"syhx2011","phase":"phase_3","mechanism":"SYHX2011 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPUU9GX21ndGt0WW1pWjVVOUZld0gtM09LcC1BLURCMjgxckI0VGV4MXduQTJ4eDNGTkN1SU8wcnBkTlFfeW5rMFlJU1FabUVTVFE1eC12czZZMzhKQzdvVU1ORmZSTjhaV3NzaHU3Rjl3WS1taXQ4dHJCV1NMb2dBVmphRldfcUpWOFRxZG9pOElaS1RmR1VtTw?oc=5","date":"2026-03-20","type":"trial","source":"openPR.com","summary":"Breast Cancer Clinical Trial Gains Momentum: 250+ Companies - openPR.com","headline":"Breast Cancer Clinical Trial Gains Momentum: 250+ Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOVDlUaWljUHVZQnpsZFFUNm1RaUxRREFfSmlzdkxRa1gyUkJoVW9HaGo4Z2M5elJIWU9PUzBLazdLRmhCQUJ1WUdQdzFtRDhtbGNKekpydVBaVVl0ZE5TY3BuWkJJV1V1NFNIbGl6bWRMNUs5eDZkUURzbV9vVjdRNFIxVEZTU1NzWGRBSklVQ3l5bTdnUDJPb0lsXzh0S0k?oc=5","date":"2026-03-09","type":"trial","source":"openPR.com","summary":"Vascular Dementia Clinical Trial Pipeline Expands as 11+ Pharma - openPR.com","headline":"Vascular Dementia Clinical Trial Pipeline Expands as 11+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNVFZfRnhhSUprYUtHanJWR0pjUWNRMGNQNnJhNWxPVjRtLVQ4VFZ6WG1ENGZqNkpuUW9nS1RjMnJkSVB3S2ZEbnZxdDJYV2VPUkY4NlNqRDctQkI4RzJud1VYUVQ5NUpKazhmME9ZT0dtdlNMMGRrY0RGZkZuSjJZTWg5blE3TEg5ajFwZFFwaw?oc=5","date":"2026-02-12","type":"deal","source":"thebambooworks.com","summary":"Big deal, bigger doubts: CSPC slides after $18.5 billion pact - thebambooworks.com","headline":"Big deal, bigger doubts: CSPC slides after $18.5 billion pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOQk8xcmM1b0pkdXBGS1kzTmZ3MUI2a0dVZDRBc0JMSlR1aEVXT3NfZGFSZ25PdlBvNmhsWEdrZjJkOHdua1lnZU5oaDNHM1lZNVN3NzBSRUpfem9CQU9KcmZtVzFJd2lTTS1TSjNjV0Y5UkdZQy1KRmZQRENvT2Z2NTVUY2FQQ2Jra0hyZ2VkVXBvM3M?oc=5","date":"2025-01-14","type":"pipeline","source":"BioWorld News","summary":"CSPC wins China clearance of new DPP-4 inhibitor - BioWorld News","headline":"CSPC wins China clearance of new DPP-4 inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOMmxuZHV2Y0NBN2xkdUhteE9TSEh2VWxEd2tlaTFPTHZ4aUVtczF3OUFNVThSZWg2SEctX2U0d1lKLWI5cE93UGxTODk0Qnk3dl9BQ1JRZmJZZlNmd2MwS2VFbWF4OXp2cjFyNnFCTUlJdl9aeE1WcVNDQU5UcmpqTlRrcmRGclZlbG43eUNiQi1maXJ1Z3JnQ1NnNVBGUQ?oc=5","date":"2024-08-26","type":"pipeline","source":"Bloomberg Law News","summary":"Ipsen Sues CSPC Pharma to Block Branded Rival to Cancer Drug - Bloomberg Law News","headline":"Ipsen Sues CSPC Pharma to Block Branded Rival to Cancer Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxQNU56YXp3SXVHRGlSLWxQTm1BdHdmN3dCeEdIakdOSHUxWEJ6ZGl6SlJfeWNUTnJDdW5SRjZCUHM0WVljTXFmMmhkWkhLS3dVY1lhWENJV2dvVzFiM1pvRlJCVE9rcUxvQlJwV3VpRzhSLUQycjI3ZzJ5RGI0Ulc0MzFJMGxYeDl4ZUxkUXBpVmxqa1dqakhKY0hNcExNX0FkQUpuZEVCd2sycjBXOTNPcnBXbVlyTkpubmNaX0NUYmFkTUVlUkk1OUZxeWVkYWtOaXJNNmpYdEFqUUJXQjJaUmQ0czhVcG43ZV82OE9CbHA5am1odlMzQ0N5WGZFX1Q4VkxvbjZKTFN0aE8zRE92V1NYNXlBRjBYY0k2M2VIU2oyVXM?oc=5","date":"2023-01-30","type":"pipeline","source":"PR Newswire","summary":"Acute Myeloid Leukemia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 200+ Companies Working in the Domain - PR Newswire","headline":"Acute Myeloid Leukemia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 200+ Companie","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE13TFU3VEx6NzVjZERyd1lWMkpYdnhQbUNBTE5hYmxRTFphNmJLX0J4dmRWa3RGTG1GX254VUlXSV9Cand2WEJveXFZamM4VktCMzRaN05UTFl1a20xSEJTT21iYUlMdUF0VGRNbHJLX1I0aXM?oc=5","date":"2021-02-16","type":"pipeline","source":"Fortune Business Insights","summary":"Vitamin B12 Market Size, Share, Growth | Industry Report [2034] - Fortune Business Insights","headline":"Vitamin B12 Market Size, Share, Growth | Industry Report [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNQXRLd1lBMHNMUGo3M0taV3dVMWl0Mko1ZTFTQ1ptUTAtcjg3eXRES0pTTkhaSXg0QkU2THYzbFIweVFibE5MbmVBR2J4ZzAwV2V6MXRFcTdPT1ZOamNaTjJtUXZWMVZyQzZZUVEzS0wyWGR0Rm4zbjdVRDVkek41VHlteDlFWWZQVmdESlhRSkpuWm5rdGtDblRwTmM?oc=5","date":"2020-02-24","type":"pipeline","source":"openPR.com","summary":"2020 Cholinesterase Inhibitors Market: Covering Prime Factors - openPR.com","headline":"2020 Cholinesterase Inhibitors Market: Covering Prime Factors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE53SnJlQk9tVUdsUWlBNmQ3czhsWWlTdmhYUUVQQjhDTkNHdjBNNWtyUnQ0V1VJMG5IWVFyTm5hYnRtT2d4Wm94ekNzLUozd3A4ZFp0ZG52QnJLZw?oc=5","date":"2017-08-01","type":"pipeline","source":"TradingView","summary":"1093 Stock Price and Chart — HKEX:1093 - TradingView","headline":"1093 Stock Price and Chart — HKEX:1093","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOdmZlN2FoYjk2UlBZNG9JdW9uZENla095VUdGamZtQ0lNelVEOG55UnAtMERuME1GYjVRcFhkQ21Pc0ZobHczUXNVR0p3MldyZjhjSHB4ekJWUEpDX01keUh3N3dKUW9ILWhGTDN0OWhhNGhQZ0xyaHlSc05hbVBndWxFZDhMSktkR1Zla0kzZ3YzRnFtcHpYNXFUX1RoSDdSSmdmX2hJQmR1ckdnb3c?oc=5","date":"2016-02-10","type":"regulatory","source":"RAPS.org","summary":"US FDA Inspections in China: An Analysis of Form 483s from 2015 - RAPS.org","headline":"US FDA Inspections in China: An Analysis of Form 483s from 2015","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}